Published in Drug Week, October 8th, 2004
With this seed funding, APT Therapeutics will initially focus its technology platforms consisting of computational drug design and therapeutic protein engineering, to develop highly promising novel stroke and anti-inflammatory pharmaceuticals.
"With the successful completion of the human genome project, protein-based technologies are key to translate genomic information into life saving therapeutics," said Ridong Chen, PhD, president and chief scientific officer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.